The weight-loss category just put up its loudest leading-indicator week of the quarter. Zepbound tops the Emerging Demand Index at 1.94, powered by a 25% week-over-week jump in Wikipedia pageviews, and it's not alone — Mounjaro, Ozempic, tirzepatide, and semaglutide all crack the top eight. When five of the top eight emerging signals are GLP-1s or their molecules, that's not noise. That's a category-level surge in consumer research intent heading into summer.

Emerging Demand — What to Watch

  • Zepbound (EDI 1.94) — Wikipedia pageviews +25% WoW, the steepest consumer-research climb in the index. No FDA action this week, so this is pure attention-driven demand, likely social and earned-media fueled.
  • Mounjaro (EDI 1.22) — Wikipedia pageviews +16% WoW. Tracking Zepbound's curve at roughly two-thirds the magnitude, consistent with cross-shopping between Lilly's diabetes and obesity brands.
  • Thyroid nodule (EDI 1.14) — Wikipedia pageviews +15% WoW, the only non-GLP-1 in the top four. Endocrinology operators should note: this often co-moves with GLP-1 awareness cycles as patients research black-box warnings, but the magnitude here is large enough to flag independently.
  • Ozempic (EDI 1.10) — Wikipedia pageviews +12% WoW plus a fresh FDA approval action on the OZEMPIC label. This is the cleanest dual-source signal in the index — consumer attention and regulatory tailwind moving together.
  • Insomnia (EDI 0.90) — Wikipedia pageviews +12% WoW, no regulatory or trial catalyst. A pure attention signal worth watching for sleep-medicine clinics, particularly as it sits outside the GLP-1 narrative.

Search Intent

Google Trends returned no breakout health queries this week, which is itself informative: the GLP-1 surge is showing up in research-grade sources (Wikipedia, FDA) rather than top-of-funnel Google queries. That pattern typically means existing patients and informed shoppers are deepening their research — a mid-funnel signal, not a cold-awareness one. Operators should weight retargeting and comparison-content spend accordingly.

Structural Markets

Arkansas remains the standout structural opportunity, running 8.5 points above the national average on hypertension (42.5% vs 34%), 4.6 points above on obesity (38.9% vs 34.3%), 3.4 points above on depression, and 3.3 points above on COPD. That's four chronic conditions stacked in one state — a rare quadruple-elevated profile. Depression also runs hot in the industrial Midwest: Michigan at 26.7% and Ohio at 26.6%, both roughly 5 points above the 21.7% national rate. Behavioral health operators planning 2H expansion should treat MI and OH as primary, AR as a chronic-care multi-line play.

Respiratory Watch

The national respiratory picture is unwinding into summer baseline. Michigan RSV is falling across 55 of 55 reporting HSAs, Texas flu falling across 49 of 49, and New York COVID and RSV both falling across all 26 reporting HSAs. The one outlier: Georgia COVID is rising across 5 of 5 reporting HSAs — small sample, but a clean directional signal worth monitoring next week.

The Bottom Line

Shift weight-loss ad budget toward mid-funnel comparison and brand-specific content this week — the Wikipedia-led surge says shoppers are deep in research, not discovery. Endocrinology clinics should pre-stage thyroid-nodule consult capacity; the 15% pageview jump is likely to convert into appointment requests within two to three weeks. And if you operate in Arkansas, this is your quarterly reminder that you're sitting on the densest chronic-disease market in the country.